Cargando…

Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature

Background: Due to the heterogeneity of hepatocellular carcinoma (HCC), hepatocelluarin-associated differentially expressed genes were analyzed by bioinformatics methods to screen the molecular markers for HCC prognosis and potential molecular targets for immunotherapy. Methods: RNA-seq data and cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Kaifei, Xu, Lin, Li, Feng, Ao, Jin, Jiang, Guojun, Shi, Rongshu, Chen, Fang, Luo, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457228/
https://www.ncbi.nlm.nih.gov/pubmed/32789471
http://dx.doi.org/10.1042/BSR20200894
_version_ 1783575958789292032
author Zhao, Kaifei
Xu, Lin
Li, Feng
Ao, Jin
Jiang, Guojun
Shi, Rongshu
Chen, Fang
Luo, Qing
author_facet Zhao, Kaifei
Xu, Lin
Li, Feng
Ao, Jin
Jiang, Guojun
Shi, Rongshu
Chen, Fang
Luo, Qing
author_sort Zhao, Kaifei
collection PubMed
description Background: Due to the heterogeneity of hepatocellular carcinoma (HCC), hepatocelluarin-associated differentially expressed genes were analyzed by bioinformatics methods to screen the molecular markers for HCC prognosis and potential molecular targets for immunotherapy. Methods: RNA-seq data and clinical follow-up data of HCC were downloaded from The Cancer Genome Atlas (TCGA) database. Multivariate Cox analysis and Lasso regression were used to identify robust immunity-related genes. Finally, a risk prognosis model of immune gene pairs was established and verified by clinical features, test set and Gene Expression Omnibus (GEO) external validation set. Results: A total of 536 immune-related gene (IRGs) were significantly associated with the prognosis of patients with HCC. Ten robust IRGs were finally obtained and a prognostic risk prediction model was constructed by feature selection of Lasso. The risk score of each sample is calculated based on the risk model and is divided into high risk group (Risk-H) and low risk group (Risk-L). Risk models enable risk stratification of samples in training sets, test sets, external validation sets, staging and subtypes. The area under the curve (AUC) in the training set and the test set were all >0.67, and there were significant overall suvival (OS) differences between the Risk-H and Risk-L samples. Compared with the published four models, the traditional clinical features of Grade, Stage and Gender, the model performed better on the risk prediction of HCC prognosis. Conclusion: The present study constructed 10-gene signature as a novel prognostic marker for predicting survival in patients with HCC.
format Online
Article
Text
id pubmed-7457228
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-74572282020-09-04 Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature Zhao, Kaifei Xu, Lin Li, Feng Ao, Jin Jiang, Guojun Shi, Rongshu Chen, Fang Luo, Qing Biosci Rep Bioinformatics Background: Due to the heterogeneity of hepatocellular carcinoma (HCC), hepatocelluarin-associated differentially expressed genes were analyzed by bioinformatics methods to screen the molecular markers for HCC prognosis and potential molecular targets for immunotherapy. Methods: RNA-seq data and clinical follow-up data of HCC were downloaded from The Cancer Genome Atlas (TCGA) database. Multivariate Cox analysis and Lasso regression were used to identify robust immunity-related genes. Finally, a risk prognosis model of immune gene pairs was established and verified by clinical features, test set and Gene Expression Omnibus (GEO) external validation set. Results: A total of 536 immune-related gene (IRGs) were significantly associated with the prognosis of patients with HCC. Ten robust IRGs were finally obtained and a prognostic risk prediction model was constructed by feature selection of Lasso. The risk score of each sample is calculated based on the risk model and is divided into high risk group (Risk-H) and low risk group (Risk-L). Risk models enable risk stratification of samples in training sets, test sets, external validation sets, staging and subtypes. The area under the curve (AUC) in the training set and the test set were all >0.67, and there were significant overall suvival (OS) differences between the Risk-H and Risk-L samples. Compared with the published four models, the traditional clinical features of Grade, Stage and Gender, the model performed better on the risk prediction of HCC prognosis. Conclusion: The present study constructed 10-gene signature as a novel prognostic marker for predicting survival in patients with HCC. Portland Press Ltd. 2020-08-28 /pmc/articles/PMC7457228/ /pubmed/32789471 http://dx.doi.org/10.1042/BSR20200894 Text en © 2020 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
spellingShingle Bioinformatics
Zhao, Kaifei
Xu, Lin
Li, Feng
Ao, Jin
Jiang, Guojun
Shi, Rongshu
Chen, Fang
Luo, Qing
Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
title Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
title_full Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
title_fullStr Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
title_full_unstemmed Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
title_short Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
title_sort identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature
topic Bioinformatics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457228/
https://www.ncbi.nlm.nih.gov/pubmed/32789471
http://dx.doi.org/10.1042/BSR20200894
work_keys_str_mv AT zhaokaifei identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature
AT xulin identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature
AT lifeng identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature
AT aojin identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature
AT jiangguojun identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature
AT shirongshu identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature
AT chenfang identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature
AT luoqing identificationofhepatocellularcarcinomaprognosticmarkersbasedon10immunegenesignature